Smad4 Deficiency Promotes Pancreatic Cancer Immunogenicity by Activating the Cancer-Autonomous DNA-Sensing Signaling...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Smad4 is crucial for transforming growth factor-β signaling and is altered in 20% of pancreatic ductal adenocarcinoma (PDAC).
• The impact of Smad4 loss on PDAC immunogenicity and the tumor immune microenvironment remains largely unknown.

Purpose of the Study:

• To investigate the role of Smad4 in regulating PDAC immunogenicity and tumor growth.
• To elucidate the underlying mechanisms by which Smad4 deficiency affects the tumor immune microenvironment.

Main Methods:

• Utilized Smad4-deficient and wild-type PDAC cell lines in immunocompetent and immunodeficient mouse models.
• Assessed tumor growth, immune cell infiltration (CD8+ T cells, cDC1s), DNA damage, and type I interferon signaling.
• Employed gene deletion strategies (Sting, Ifnar1, cDC1 deficiency) to dissect the mechanism.

Main Results:

• Smad4 deficiency inhibited in vivo PDAC tumor growth in immunocompetent mice, but not in immunodeficient or CD8+ T cell-depleted mice.
• Smad4 loss increased tumor immunogenicity by inducing DNA damage and activating STING-mediated type I interferon signaling.
• This pathway led to enhanced activation of type 1 conventional dendritic cells (cDC1s) and CD8+ T cells, mediating tumor control.
• Tumor growth inhibition was reversed upon Sting, Ifnar1, or cDC1 deficiency, confirming the mechanism.

Conclusions:

• Smad4 loss unexpectedly suppresses PDAC tumor growth by enhancing immunogenicity through intrinsic DNA damage and STING-dependent type I interferon signaling.
• This pathway activates cDC1s and CD8+ T cells, highlighting a novel mechanism of tumor immune surveillance in PDAC.